Naveen Pemmaraju, MD, of the MD Anderson Cancer Center, Houston, TX, highlights the importance of raising awareness for rare diseases and underlines the value of molecular subtyping in hematological malignancies to enable the development of targeted therapies as well as provide personalised medicine to rare disease patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).